Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET

Company Participants

Luis Sanay - Head, IR

John Jacobs - President and CEO

Jeffrey Dierks - Chief Commercial Officer

Jeffrey Dayno - Chief Medical Officer

Sandip Kapadia - CFO

Conference Call Participants

Chris Howerton - Jefferies

Danielle Brill - Raymond James

Charles Duncan - Cantor Fitzgerald

Graig Suvannavejh - Goldman Sachs

Corinne Jenkins - Goldman Sachs

David Amsellem - Piper Sandler

Francois Brisebois - Oppenheimer

Operator

Good morning, my name is Katie and I'll be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Second Quarter 2022 Financial Update Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference maybe recorded. [Operator Instruction] I would now like to turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead, sir.

Luis Sanay

Thank you, operator. Good morning everyone and thank you for joining us today as we review Harmony Biosciences second quarter 2022 financial performance and provide a business update. Before we start, and encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performing.

Our presenters on today's call are John Jacobs, President and CEO; Dr. Jeffrey Dayno, Chief Medical Officer; Jeffrey Dierks, Chief Commercial Officer; and Sandip Kapadia, Chief Financial Officer.

Moving on to slide two. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, our actual results may differ materially and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details.

I would now like to turn the call over to our CEO, John Jacobs. John?

John Jacobs

Thank you, Luis, and thank you everyone for joining our conference call today. We are excited about the momentum we saw in our business as we continue to execute on our three pillar growth strategy during the second quarter. We made good progress in the first half of this year and are looking forward to making 2022 our best year yet for Harmony.